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Figure 2: 10-year allocated and actual use of CEA 
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Figure 3: 10-year risks of A. any stroke or perioperative death, B. any non-perioperative stroke 
(After year 10 there were no perioperative strokes and 4 Immediate vs 7 Deferred first strokes.) 
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Figure 4: Current use (at or after randomisation) of various medical treatments by year of follow-
up and by original treatment allocation (to Immediate or Deferred CEA) 
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Figure 5: 10-year risks, by current lipid lowering therapy (at or after randomisation) 
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Figure 6: 10-year risks, males and females < 75 (mean 66) years of age at entry 
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Figure 7: Non-perioperative strokes, by outcome and subtype
Category
Events/person-years and
annual event rate (%)
Immediate CEA Deferral
Immediate CEA events
Logrank
O-E
Variance
of O-E
Ratio of annual event rates
Immediate CEA:Deferral [95% CI]
(a) Outcome of the worst stroke
Fatal or disabling* 62 (0.64%) 104 (1.05%) -20.22 41.49 0.61 [0.41-0.92]
Non-disabling only 37 (0.39%) 84 (0.88%) -23.55 30.25 0.46 [0.29-0.73]
(b) Territory of the first stroke
Ipsilateral 38 (0.40%) 92 (0.96%) -27.06 32.50 0.43 [0.28-0.68]
Contralateral 39 (0.41%) 64 (0.67%) -12.54 25.75 0.61 [0.37-1.02]
Vertebrobasilar 11 (0.11%) 23 (0.24%) -5.99 8.50 0.49 [0.20-1.20]
Unknown 11 (0.11%) 9 (0.09%) 1.00 5.00 1.22 [0.39-3.87]
(c) Aetiology of the first stroke
Haemorrhagic 13 (0.14%) 13 (0.14%) -0.04 6.50 0.99 [0.36-2.73]
Probably
   cardioembolic¶ 21 (0.22%) 24 (0.25%) -1.55 11.25 0.87 [0.40-1.88]
Other ischaemic 43 (0.45%) 104 (1.09%) -30.53 36.75 0.44 [0.28-0.67]
of which:
   definitely lacunar 7 (0.07%) 24 (0.25%) -8.45 7.75 0.34 [0.13-0.85]
Unknown 22 (0.23%) 47 (0.49%) -12.45 17.25 0.49 [0.26-0.90]
99/9582
(1.03%)
188/9556
(1.97%)
-44.57 71.74Any first stroke 0.54 [0.43-0.68]
2p < 0.0001
1.00.0 1.50.5
Immediate CEA
better
Immediate CEA
worse
99% or 95% confidence interval
*  Includes all patients who eventually died of stroke or were disabled by a stroke,
      irrespective of the nature of their first stroke
¶ Any non−haemorrhagic stroke in a patient with atrial fibrillation
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Figure 8: First non-perioperative stroke by current medical treatment
Category
Events/person-years and
annual event rate (%)
Immediate CEA Deferral
Immediate CEA events
Logrank
O-E Var
Ratio of annual event rates
Immediate CEA:Deferral [95% CI]
On lipid-lowering therapy before any stroke?
Yes 45/6623 (0.7%) 88/6568 (1.3%) -21.89 33.24 0.52 [0.33-0.81]
No 54/2959 (1.8%) 100/2988 (3.3%) -22.49 38.48 0.56 [0.37-0.84]
On both lipid-lowering and antithrombotic therapy before any stroke?
Yes 45/6615 (0.7%) 88/6561 (1.3%) -21.88 33.24 0.52 [0.33-0.81]
No 54/2967 (1.8%) 100/2995 (3.3%) -22.53 38.48 0.56 [0.37-0.84]
On lipid-lowering, antithrombotic and antihypertensive therapy before any stroke?
Yes 43/6254 (0.7%) 79/6111 (1.3%) -18.84 30.48 0.54 [0.34-0.86]
No 56/3328 (1.7%) 109/3445 (3.2%) -25.00 41.21 0.55 [0.36-0.81]
99/9582 (1.0%) 188/9556 (2.0%) -44.57 71.74Total 0.54 [0.43-0.68]
2p < 0.0001
1.00.0 1.50.5
Immediate CEA
better
Immediate CEA
worse
99% or 95% confidence interval
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Figure 9: First non-perioperative stroke, by subgroup
Category
Events/person-years and
annual event rate (%)
Immediate CEA Deferral
Immediate CEA events
Logrank
O-E Var
Ratio of annual event rates
Immediate CEA:Deferral [95% CI]
Years since randomisation
Years 0-5 56/6540 (0.9%) 140/6553 (2.1%) -41.82 48.99 0.43 [0.29-0.62]
Years 5-10 43/3042 (1.4%) 48/3003 (1.6%) -2.74 22.75 0.89 [0.52-1.52]
Heterogeneity test: χ 2
1
 = 8.4; p = 0.004
Year of randomisation
1993-6 51/5037 (1.0%) 110/4990 (2.2%) -29.75 40.24 0.48 [0.32-0.72]
1997-9 35/2728 (1.3%) 45/2762 (1.6%) -4.66 19.98 0.79 [0.45-1.41]
2000-3 13/1817 (0.7%) 33/1804 (1.8%) -9.92 11.49 0.42 [0.20-0.90]
Sex
Men 66/6238 (1.1%) 127/6087 (2.1%) -31.53 48.23 0.52 [0.36-0.75]
Women 33/3344 (1.0%) 61/3469 (1.8%) -13.08 23.48 0.57 [0.34-0.97]
Age at entry (years)
< 65 (mean 59) 25/3098 (0.8%) 54/2946 (1.8%) -15.44 19.72 0.46 [0.26-0.82]
65-74 (mean 70) 44/4832 (0.9%) 96/4909 (2.0%) -25.45 34.99 0.48 [0.31-0.75]
≥  75 (mean 78) 30/1652 (1.8%) 38/1701 (2.2%) -3.57 16.99 0.81 [0.43-1.51]
Sex and age at entry
Men < 75 53/5272 (1.0%) 105/5063 (2.1%) -27.40 39.47 0.50 [0.33-0.75]
Women < 75 16/2658 (0.6%) 45/2792 (1.6%) -13.73 15.23 0.41 [0.21-0.79]
Men ≥  75 13/965 (1.3%) 22/1024 (2.1%) -4.08 8.74 0.63 [0.26-1.50]
Women ≥  75 17/687 (2.5%) 16/677 (2.4%) 0.27 8.24 1.03 [0.42-2.53]
Prerandomisation cholesterol (mmol/L)
< 6.5 (250 mg/dL) 75/6282 (1.2%) 117/6462 (1.8%) -19.61 47.98 0.66 [0.46-0.96]
≥ 6.5 20/2846 (0.7%) 64/2643 (2.4%) -23.29 20.96 0.33 [0.19-0.58]
Not measured 4/454 (0.9%) 7/451 (1.6%) -1.50 2.74 0.58 [0.12-2.74]
Prerandomisation systolic blood pressure (mm Hg)
< 160 48/5470 (0.9%) 103/5527 (1.9%) -27.09 37.72 0.49 [0.32-0.74]
≥ 160 51/4112 (1.2%) 85/4029 (2.1%) -17.54 33.97 0.60 [0.38-0.93]
Ipsilateral carotid diameter reduction (% by ultrasound)
< 70 (mean 59) 13/976 (1.3%) 23/989 (2.3%) -4.84 8.99 0.58 [0.25-1.38]
70-79 (mean 72) 28/3091 (0.9%) 59/3023 (2.0%) -15.91 21.75 0.48 [0.28-0.84]
80-89 (mean 81) 25/2522 (1.0%) 58/2754 (2.1%) -14.69 20.71 0.49 [0.28-0.87]
90-99 (mean 92) 33/2993 (1.1%) 48/2789 (1.7%) -8.76 20.22 0.65 [0.37-1.15]
Ipsilateral plaque echolucency (% soft material)
< 25 23/2486 (0.9%) 47/2556 (1.8%) -11.63 17.49 0.51 [0.28-0.95]
≥ 25 28/2294 (1.2%) 47/2546 (1.8%) -7.59 18.70 0.67 [0.37-1.21]
Not estimated 48/4802 (1.0%) 94/4453 (2.1%) -25.57 35.45 0.49 [0.32-0.75]
Ipsilateral carotid territory status at entry: previous symptoms
None before entry 85/8501 (1.0%) 165/8472 (1.9%) -40.14 62.49 0.53 [0.38-0.73]
>6 months previous 14/1081 (1.3%) 23/1084 (2.1%) -4.53 9.24 0.61 [0.26-1.43]
Contralateral status at entry: previous symptoms (yes/no), CEA history, and patency
No, no CEA, patent 56/6452 (0.9%) 109/6690 (1.6%) -24.97 41.23 0.55 [0.37-0.82]
Yes, CEA, patent 18/1443 (1.2%) 32/1358 (2.4%) -7.69 12.48 0.54 [0.26-1.12]
Yes, no CEA, patent 15/840 (1.8%) 29/772 (3.8%) -7.66 10.97 0.50 [0.23-1.08]
Occluded 10/846 (1.2%) 18/736 (2.4%) -4.91 6.96 0.49 [0.19-1.31]
Diabetes or ischaemic heart disease (IHD) recorded at entry
Diabetes 23/1657 (1.4%) 44/1651 (2.7%) -10.32 16.73 0.54 [0.29-1.01]
IHD, non-diabetic 25/2375 (1.1%) 48/2541 (1.9%) -10.26 18.22 0.57 [0.31-1.04]
Neither 51/5550 (0.9%) 96/5364 (1.8%) -23.67 36.73 0.53 [0.34-0.80]
Antihypertensive therapy at entry?
Yes 71/6073 (1.2%) 113/6019 (1.9%) -21.40 45.99 0.63 [0.43-0.92]
No 28/3509 (0.8%) 75/3537 (2.1%) -23.23 25.73 0.41 [0.24-0.67]
Antithrombotic therapy at entry?
Antiplatelet only 87/8535 (1.0%) 165/8267 (2.0%) -40.96 62.97 0.52 [0.38-0.72]
Anticoagulant only 4/435 (0.9%) 12/455 (2.6%) -3.83 3.99 0.38 [0.11-1.39]
Both 1/77 (1.3%) 2/138 (1.5%) -0.07 0.69 0.90 [0.04-20.09]
Neither 7/535 (1.3%) 9/696 (1.3%) -0.10 3.95 0.98 [0.27-3.57]
Lipid lowering therapy at entry?
Yes 21/2800 (0.8%) 46/3027 (1.5%) -11.24 16.72 0.51 [0.27-0.96]
No 78/6782 (1.2%) 142/6529 (2.2%) -33.91 54.97 0.54 [0.38-0.76]
99/9582 (1.0%) 188/9556 (2.0%) -44.57 71.74Total 0.54 [0.43-0.68]
2p < 0.0001
Global sum of heterogeneity tests (between black squares): χ 2
27
 = 29.4; p = 0.34
1.00.0 1.50.599% or 95% confidence interval
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Table 1: Surgical compliance, mortality and morbidity 
 
 Allocated 
immediate CEA
(n=1560) 
Allocated 
deferral of any CEA 
(n=1560) 
Surgical compliance 
Number of patients with any CEA 1425 (91.3%) 407 (26.1%) 
Proportion with any CEA (%)*   
Within 1 year 89.8 7.5 
Within 5 years 92.4 23.5 
Within 10 years 92.5 34.1 
   
Non-symptomatic CEA (ie, CEA in patients without any prior symptoms) 
Proportion with non-symptomatic CEA (%)* 
Within 1 year 89.7 4.8 
Within 5 years 92.1 16.5 
Within 10 years 92.2 23.5 
   
Ipsilateral CEA   
Proportion with ipsilateral CEA (%)* 
Within 1 year 88.9 6.9 
Within 5 years 91.5 21.3 
Within 10 years 91.6 29.8 
   
Contralateral CEA   
Proportion with contralateral CEA (%)* 
Within 1 year 2.9 0.8 
Within 5 years 5.5 4.0 
Within 10 years 7.7 7.5 
Perioperative mortality and morbidity 
Total number of CEAs† 1532 447 
Stroke death 11 2 
Cardiac death 5 0 
Other death 1 1 
Disabling stroke 9 5 
Non-disabling stroke 18 8 
Non-fatal myocardial infarction 10 1 
Any perioperative stroke or death 44 16 
% of total number of CEAs (95% CI) 2.9 (2.1-3.8) 3.6 (2.2-5.7)
 
This table includes only CEAs done within 10 years of randomisation. 
CEA=carotid endarterectomy  
* Kaplan-Meier time-dependent percentages; denominators at these times are 
shown in figure 2.  
† Ipsilateral or contralateral (bilateral=two CEAs) first or subsequent CEAs. 
.
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Table 2A: Cause-specific numbers of deaths within 10 years. 
 Number of deaths Logrank 
p-value  Both groups Immediate CEA Deferral 
ACST-outcome-related mortality 
Perioperative (ie, after CEA)  20  17  3  0.002 
Non-perioperative stroke  107  39  68  0.006 
Other (ie, intercurrent) mortality 
Vascular  565  298  267  0.15 
Neoplastic  212  111  101  0.44 
Other/unknown  276  145  131  0.33 
 
 
Table 2B: Intercurrent mortality: 10-year risks of death from causes other than 
main ACST outcomes, by sex and by age at entry* 
 Male Female 
Age at entry   
< 75 years (mean 66) 44% 31% 
≥ 75 years (mean 78) 74% 60% 
* Calculated by life-table methods (censored at the time of death from stroke or from the perioperative hazards of CEA) 
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ACST-1 Protocol 2001 – page 2
Summary  of Protocol Procedure
1. Consider ALL patients with uni- or bilateral carotid stenosis for ACST-1.  Ultrasound both
carotids - estimate % stenosis and plaque composition.  Assess risk factors, do CT brain
and neurological examination.  If coronary artery by-pass (or angioplasty) needed, do this
before entering the trial.  If carotid artery under consideration is asymptomatic for 6 months
or more, and patient is fit and willing for operation (if randomised to this treatment) and
follow-up, ENTER INTO ACST-1.
2. Obtain written patient consent, prepare randomisation data and telephone Oxford
(if unable to telephone, then fax).
TREATMENT ALLOCATED: either (1) Best Medical Treatment (BMT)
or (2) BMT plus carotid endarterectomy
3. Begin treatment as soon as possible.
If randomised to carotid endarterectomy, operate on next available routine operating list.
(N.B. Any stroke or death pre-op. will be in the surgery group!)
Postoperatively, before discharge, neurological re-examination of patient.
ANY postoperative (<30 days) stroke or death - MAJOR EVENT form.
Best Medical Treatment for ALL patients during follow-up.
4. FOLLOW-UP:
Carotid duplex and clinical interview 4 months, 1, 2, 3, 4, 5 years post-randomisation for at
least 5 years  - please return forms promptly.
Any stroke or death report immediately on MAJOR EVENT form.
Inform ACST-1 if patient or relatives change address (or change GP in UK).
ACST office (for queries, follow-ups, major events and problems):
telephone: +44 (0)20 8725 3746
fax: +44 (0)20 8725 3782
email: acst@sghms.ac.uk
Oxford CTSU (randomisation only):
telephone: +44 (0)1865 240972
fax: +44 (0)1865 404849
PLEASE READ THE FULL PROTOCOL.
CALL, WRITE, OR FAX TO US AT THE ACST
OFFICE ABOUT ANYTHING WHICH YOU FIND UNCLEAR.
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ACST-1 Protocol 2001 – page 3
ACST-1 Trial Protocol
I n t ro duc t ion
The current incidence of stroke in Europe and the USA is about 200 per 100,000 population
per annuml,2.  Eighty percent of strokes are ischaemic and 20% are due to haemorrhage.
Approximately half the patients with ischaemic stroke have carotid artery stenosis3 and
about one third (~10% all stroke victims) have had no warning symptoms such as transient
ischaemic attacks4.
European Carotid Surgery Trial (ECST)5 and North American Symptomatic Carotid
Endarterectomy Trial (NASCET)6 have effectively shown that carotid endarterectomy (CEA)
can prevent strokes in symptomatic patients.  The benefit of operation is, at present,
confirmed in those with at least 70% stenosis; for 50-69%, the results are somewhat
equivocal7.  In asymptomatic patients the Veterans Administration Study8 and the
Asymptomatic Carotid Atherosclerosis Study (ACAS)9 suggested  that surgery may reduce
the overall risk of TIA and stroke.  There is as yet no convincing evidence in asymptomatic
patients that moderate or severe stroke (or death) can be prevented by CEA.  The aim of
this trial is to determine whether CEA and appropriate best medical treatment (BMT) can
improve stroke free survival time when compared with BMT alone.
B ackg round
Asymptomatic carotid stenosis (ACS) can be accurately and non-invasively detected by
ultrasound10,11.  It is often found in patients with contralateral symptomatic stenosis or
vascular disease elsewhere, but routine ultrasound screening is also justified in certain
population groups.  Stenosis of more than 50% is present in ~25% hypertensive patients12,
and in ~12% of those with peripheral vascular disease.  Other groups worth screening
include those over 60 years who are known to have ischaemic heart disease, aneurysms or
hyperlipidaemia, and are smokers13,14,15.
ACS may be an important causative factor in unheralded stroke.  Two factors, accurately
detectable by ultrasound, are particularly important; severity of stenosis and composition
of the stenotic plaque.  Approximately three quarters of strokes which do occur in natural
history studies of ACS are ipsilateral to the side with severe stenosis, implicating the carotid
stenosis as the cause of stroke16.  Bilateral stenosis may carry even greater risk, especially if
the patient has an incomplete circle of Willis.  There is evidence of higher risk in patients
with contralateral occlusion, reduced collateral circulation (measured by transcranial
Doppler) and progressively occlusive carotid disease17.
The type of plaque causing stenosis appears to have important prognostic significance.
Ultrasonically echolucent material is, when examined histologically, soft and friable and
echogenic plaque is firm and collagenous18.  Several studies have demonstrated that patients
with predominantly ‘soft’ plaques are more likely to have suffered previous TIAs or
strokes19,20,21,22.  Prospectively, by following patients using serial ultrasound, Langsfield and
Bock found that both type and degree of stenosis were positively associated with
subsequent development of symptoms23,24.
Although stroke risk is thought to be greatest with stenosis >80%, Satiani showed that
patients with >50% stenosis had a 7% risk of stroke after 2 years25 and Moore found that
after 5 years one third of hypertensive patients with similar stenoses had had a stroke26.
Johnson reported that “even patients with <75% narrowing are at increased risk if the
plaque was heterogeneous or soft” and, after 3 years, 20% of patients in this study had
either had a TIA or stroke27. Clearly an effective preventative therapy was needed.
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Med ica l  t rea tment  o f  ACS
Treatment of modifiable medical risk factors is appropriate in all patients.  Meta-analysis of hypertension
trials showed that reduction of systolic blood pressure by 5-6 mmHg was associated with 35-40%
fewer strokes and 20-25% fewer myocardial infarctions28. Recommended ‘safe’ blood pressure limits
have been repeatedly lowered29. Regular aspirin usage has been found to reduce deaths from
myocardial infarction and non-fatal strokes in symptomatic patients30.
Lipid-lowering therapy may, by reducing total and LDL cholesterol and fibrinogen, effect plaque
regressions31.  It has certainly been shown to reduce the incidence of symptomatic coronary heart
disease.  Control of diabetes is important as, although strokes may still occur, prevention of
hyperglycaemia may attenuate stroke severity32.  Smoking directly effects the incidence of carotid
stenosis and although there is no evidence yet to suggest that stopping smoking will slow, stop or
reverse ACS, it should be strongly discouraged33. Heavy alcohol consumption has been associated
with hypertension and haemorrhagic stroke and should be reduced34.  Myocardial infarction is
commoner than stroke in patients with ACS and discovery of carotid stenosis is a golden opportunity
to uncover and treat heart disease35.  Patients with ACS may be non-invasively investigated by
ECG and exercise testing, or by modified studies such as ECG chest wall mapping or dipyridamole-
thallium exercise scanning36.  In some cases, coronary angiography and subsequent angioplasty
or by-pass surgery may be necessary.  The asymptomatic carotid artery does not usually have to be
operated upon when coronary artery by-pass is undertaken37.
S u rg ery  fo r  ACS
Because carotid endarterectomy can be performed with low perioperative morbidity and
mortality, surgeons may be tempted to operate.  In a collective review of over 2300
endarterectomies for ACS, Colburn found that the perioperative stroke rate and 30-day
mortality was 1.5% and 0.8% respectively38. Comparisons of outcome with and without surgery
may suggest that surgery is beneficial; Moneta in 1987 reported that 19% of patients with
>80% stenosis had strokes or died within 2 years, in contrast to 5.8% of the surgically treated
group39.  Bias occurs within non-randomised trials however, and even ‘natural history’ studies
do not include patients who have been pre-selected for surgery, potentially altering results.
C l in i ca l  Tr i a l s  o f  ACS
The ideal means of investigating the importance of ACS should be a clinical trial.  The North
American and European symptomatic carotid surgery trials (ECST and NASCET) have
successfully demonstrated the value of endarterectomy for symptomatic carotid stenosis5,6.
But, to date, four trials of surgery for ACS have been inconclusive.
The Mayo Clinic trial (MACE) compared aspirin with surgery and was terminated after only
71 patients had been entered because an excess of patients in the surgical group had myocardial
infarctions40.
CASANOVA, a German trial, took ten years, reporting in 199141.  Four hundred and ten
patients in 10 centres were entered.  All were given aspirin and were completely asymptomatic.
Patients with >90% stenosis were excluded, and several different treatment options such as
unilateral or bilateral endarterectomy, and unilateral endarterectomy or medical treatment
were permitted.  Operative intervention occurred frequently during medical patients’ follow
up (e.g. if bilateral stenoses exceeded 50%).  The trial end points were stroke and death.  The
trial was stopped when only 122 patients, who had unilateral surgery, were available for
comparison with 111 who had medical treatment.  At this point only 9.8% of the unilateral
surgical group and 12.6% of the medical group had reached an endpoint (p=0.321). The trial
organisers concluded that “at least 2000 randomised patients are needed to detect 25-33%
reduction of stroke risk.. (and this information).. will not be available from one single study
but will require meta-analysis of all available trials”.
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The Veterans’ Administration trial (#167) ran from 1983-917.  Only men were eligible
and 444 out of a target of 500 were recruited.  Patients with previous ipsilateral cerebral
infarction (clinical or CT) were excluded and the endpoints were TIA, stroke and death.
After TIA, crossover to surgery was permitted.  For stroke prevention, results were again
inconclusive, but 12.8% of the surgical group had stroke or TIAs compared with 24.8% of
the medical group.  They concluded that “to detect a reduction of 50% in strokes in the
surgical group would require more than 3000 patients – beyond the scope of any
contemporary clinical trial” in ACS.
Currently, the largest clinical trial is the Asymptomatic Carotid Artery Study (ACAS)8
in the US, which recruited 1662 patients.  The minimum preoperative stenosis was 60%,
with angiography compulsory in the operated group42. The trial, using projected life table
analysis to 5 years, showed a reduction in expected ipsilateral stroke rate from 2% per
annum to 1% per annum in the surgical group.  A subgroup analysis to identify higher
risk groups (for example, those with soft plaque or greater than 90% stenosis) was not
possible, and the results still leave many questions unanswered.
In ECST and NASCET four CEAs needed to be carried out to prevent one disabling stroke
in patients with 70-99% symptomatic stenosis.  To date, the ACAS results have not yet
been able to show that surgery can reduce the risk of disabling strokes.  This study is now
terminated and high risk groups have not been identified.  Therefore the ACST-1 is the only
continuing study to determine the value of operation in effectively preventing stroke in
asymptomatic patients.
The ACAS results have not yet been shown to be generalisable; the American Heart
Association guidelines43 recommended CEA only if operative mortality and morbidity was
<3.0%. Several large studies44,45 have shown that operative mortality and morbidity may
exceed 4-5%, suggesting that medical therapy may be safer than operation.
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The Asymptomatic Carotid Surgery Trial (ACST-1)
Aim o f  the  t r i a l
This is a multi-centre randomised trial of carotid endarterectomy (CEA) in patients with
asymptomatic carotid artery stenosis.
The aim is to determine whether CEA and best medical treatment (BMT) improve stroke-
free survival time when compared with best medical treatment alone.  The trial will also
identify high risk groups in whom the benefits of surgery and of best medical treatment
may be greater.
E l ig ib i l i t y
Patients whose carotid stenosis has not caused symptoms for at least 6 months, who have
no past history of ipsilateral disabling or severe contralateral stroke, and who have no
indications for, or contra-indications to carotid endarterectomy, are eligible for ACST-1.
Patients already in ECST cannot be entered into this Trial as a patient can only be randomised
once, even though they have two carotid arteries.
The participating neurologist should ensure that they are asymptomatic.  If they have
residual neurological signs but have nevertheless no symptoms to specific
questioning, then they are asymptomatic.  The presence of residual signs should be
recorded by the neurologist and the patient considered eligible for the trial.
It is well known that the commonest cause of death in patients with carotid stenosis is
ischaemic heart disease and screening for this, even in patients without symptoms, is
strongly encouraged.
Patients are therefore eligible if in the view of the responsible physician or surgeon:
1) They have unilateral or bilateral carotid artery stenosis appropriate for surgery. The
severity of stenosis is not defined specifically - some will have stenoses >90% and
some may have stenosis of ~50% with soft plaque; patients with contralateral
occlusion may be randomised.  The patient may be entered into ACST-1 if the
surgeon is satisfied that the lesion is clinically and technically appropriate
to operate on, if randomised to that option.
2) The patient is fit for, and willing to have surgery if recommended and accessible for
follow-up, with no known illness preventing long-term follow-up.
3) There is substantial uncertainty about whether the patient is better treated by surgery
and appropriate medical treatment or by medical therapy alone.
Reasons for not entering patients into the Trial are specified by the responsible surgeon
or physician, not by the protocol, but include:
1) a small likelihood of worthwhile benefit such as:-
(i) low risk of cerebral infarction from a smooth calcified
carotid plaque not causing significant stenosis;
(ii) some major life-threatening disease other than stroke.
2) a high risk of adverse effects of trial treatment such as:
(i) recent acute myocardial infarction;
(ii) intracerebral neoplasia or aneurysm.
3) Restenosis of the artery following previous CEA.
4) Patients with a likely cardiac source of emboli.
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Co n sent  fo r  Ent ry  in to  ACS T - 1
The degree of consent is left to individual doctors to decide for individual patients in the
light of any advice they may receive from their local Ethical Committee.  However, written
consent is required and any consent required should be sought before randomisation.  At
all times the local requirements for operative surgery consent should be met and if necessary,
a full description of the operation and perioperative care provided.  This should also be
taken to include appropriate consent for invasive radiological procedures if they are
undertaken in trial patients.  The collaborating surgeons and physicians will be responsible
for patient care in the normal way and the trial should not alter their normal practice.
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Choice of Treatments
B es t  Med i ca l  Trea tme nt  ( fo r  ALL  pa t ie nt s )
Patients’ ‘best medical treatment’ is extremely important . Risk factors for stroke and death (the
trial end-points) specifically targeted are smoking, hypertension, diabetes, obesity, hyperlipidaemias,
polycythaemia and ischaemic heart disease.  These should all be rigorously managed.
As randomisation will be within centres, slight differences in medical management between centres
should not influence overall results but all centres will be expected to ensure that all patients
receive optimal care.  Although treatment is only recorded at trial follow-up, it should be strictly
adhered to and the controlling physician should, by appropriately frequent visits, ensure patient
compliance.
Smoking should be strongly discouraged and if possible stopped completely.
Hypertension should be controlled within ‘safe’ limits (a systolic blood pressure consistently >140
mmHg and a diastolic pressure consistently >90 mmHg may be generally considered to confer a
higher than normal risk of stroke).
Diabetes should be recognised, treated and controlled.
Ischaemic Heart Disease, whether symptomatic or uncovered by investigation should be
appropriately treated.  Treatment of coronary artery disease by angioplasty or by-pass surgery is
not a contra-indication for future entry into ACST-1 (however, in this trial CEA cannot be performed
simultaneously with coronary by-pass surgery).  Entry into ACST-1 should be as soon as the patient is
considered fit for further surgery after by-pass or angioplasty has been successfully performed.
Hyperlipidaemia should be treated.  Cholesterol level should ideally be <5.0 mmol/l.
AntipIatelet therapy may be considered as ‘best medical treatment’ unless the patient is already
on long-term anticoagulants, e.g. warfarin, or there is a specific contraindication to aspirin or
clopidogrel treatment such as allergy or gastrointestinal haemorrhage.
Anti-coagulant drugs may be given as part of treatment for other conditions, e.g., mitral valve
replacement or if TIAs continue after surgery despite antiplatelet therapy (mitral valve cases should
not be in the trial), or as part of therapy for disease related to carotid stenosis, e.g., femoro-distal
by-pass grafting using PTFE.
Su rg i ca l  Trea tment  (50% pa t ie nt s )
Carotid endarterectomy should be carried out as soon as routinely possible if the patient
is randomised to surgical treatment.  The surgeon may wish to undertake preoperative
angiography before or after randomisation.  This is not mandatory as some surgeons now
perform CEA without angiography.
CEA may not be scheduled before, or at the same time as planned elective coronary artery
by-pass surgery. The carotid endarterectomy technique is that with which the surgeon is
familiar.  Specific procedures, such as shunting, are undertaken at the surgeon’s discretion.
The surgeons collaborating in this trial will already have experience in undertaking CEA in
patients who are symptomatic and have clear clinical indications for surgery. The surgeon
collaborators should have a track record of their own results which should compare
favourably with standards elsewhere in Europe and the USA.  Before becoming a
collaborator in ACST-1, each surgeon submits a record of their last 50 endarterectomies,
specifying the number done for asymptomatic disease, and the number of disabling strokes
or deaths occurring within 30 days of surgery.  They should keep on-going records of their
results and will be asked on a yearly basis to submit the numbers of CEAs undertaken with
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indications for surgery.  Specific results will not be requested for operations outside the
Trial.  However, if an individual surgeon’s results in this trial show an unacceptably high
morbidity or mortality (as found by the Audit Committee) they may be asked not to enter
any further patients.  Complete follow-up on those already entered will be necessary and
the collaborator would be asked to continue within the Trial on a ‘follow-up only’ basis.
Following surgery, and before discharge, patients should be assessed by the neurologist
to ensure there is no neurological deficit.  If one is uncovered, the patient should be
investigated for stroke and the major event form completed and returned.  Routine
postoperative and follow-up treatment usually includes antiplatelet therapy.
No surgery form is required by the ACST office.  However, if the patient has a stroke or
dies, a major event form must be filled out and returned as soon as possible.  All details
which may be relevant (e.g. operative procedure, postoperative course and complications)
should be recorded within the patient’s notes and will then be of help in filling out the
major event form.  As major events will eventually provide the Trial end points, these
details are of vital importance.  A telephone call or fax should be sent to the ACST office
to indicate that surgical complications have occurred as soon as the events take place;
details can then be provided on the form.
Te Iep ho ne  Randomisa t ion :  Ma de  e a sy  wi th  the
Ran d o misat ion  Notepa d
No entry form is needed for ACST-1 and no unusual tests are required.  Entry is by means of
a direct dial telephone call (or fax) to the randomisation service in Oxford to answer a few
questions about the patient.  Calls should be made between 0900-1700 UK time. The
telephone call is made easier and quicker by use of the randomisation notepad to prepare
answers for the questions:
a) Name and country of surgeon or agreed collaborator in charge.
b) Patient name, date of birth, sex.
c) Relative - name and phone number/address
(in UK or the Netherlands give GP’s name and postcode).
d) Current therapy and blood pressure.
e) Carotid artery history, evidence of infarct on brain scan, presence of echolucent
plaque and estimate (%) of carotid stenosis.
f) Intention (if surgery drawn) to operate on left or right artery.
At the end of the telephone call after the pre-randomisation details have been provided,
and written patient consent has been confirmed, the randomisation service allocates the
patient’s treatment: either best medical treatment and surgery, or best medical treatment
alone.  All patients are then irrevocably in the trial whether treatment is carried out or
not since the trial analysis will be on ‘intent to treat’.  Surgery should therefore be carried
out as soon as possible on a planned elective basis, and any surgical complications reported
as soon as they occur.
Fo l lo w-up  and  the  dev e lopme nt  o f  sy mptoms  o r
ma jo r  ev ents
In contrast to ECST, the surgeon is usually the physician who screens for, detects and initally
assesses the majority of patients with asymptomatic carotid stenosis.  This may not be the
case in all European countries or in all practices.
Follow-up is best done by the neurologist (or stroke physician) in collaboration with the
surgeon wherever possible.  During trial follow-up all patients should be seen at 4 months
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after randomisation, 12 months, and yearly thereafter.  An up-to-date duplex Doppler
examination of both carotid arteries should be carried out at each follow-up visit, if possible.
The follow-up is simple, requiring answers for the questions:
a) Name of surgeon or agreed collaborator, and date.
b) If randomised to surgery; date and side.
c) Any clinical myocardial infarct.
d) Any other carotid surgery since last follow up; and date, and side.
e) Any carotid symptoms either side; stroke, death, and date.
f) Current duplex stenosis, (where practicable), any definite increase in plaque
echolucency.
g) Current drug therapy and blood pressure.
If patients develop neurological symptoms (not stroke) they must be seen and assessed
promptly by the neurologist.  If the patient has a stroke, assessment by the collaborating
neurologist (including CT scan) should be carried out promptly and a major event form
completed and returned to the ACST office.  Appropriate clinical action should be taken
which may include patients on medical treatment alone going on to have CEA.  This does
not exclude them from the trial and follow-up should continue on the same basis for all
patients.  All patients remain within in the trial until the trial is completed.
Du p lex  Repor t ing
At randomisation and follow-up the estimated stenosis and plaque composition is entered.
If possible the following simple duplex data should be separately recorded (by the
collaborator or the vascular laboratory staff) and sent to the ACST office .
Majo r  events  and  s t rok e  c l a s s i f i ca t ion
Strokes and deaths should be immediately reported as they are major events. The audit
committee classifies them when adequate information, including modified Rankin scoring
for strokes has been received. Copies of the clinically relevant data such as ECG, CT/MR
scans and post-mortem reports may be requested. (The cost of sending copies of relevant
CT/MR scans will be supported, at present up to £20 sterling.)
If a patient dies, the major event form should be completed and returned.  There is only
one double sided form to return, covering follow up and major events.
Patient name:   
Surname  Forename
Date of examination (day/month/year): / /
Left Right
PSV (CCA)= cm/s PSV (CCA)= cm/s
EDV (CCA)= cm/s EDV (CCA)= cm/s
PSV (CCA)= cm/s PSV (CCA)= cm/s
EDV (CCA)= cm/s EDV (CCA)= cm/s
Doppler angle = º Doppler angle = º
% stenosis = % % stenosis = %
Is >25% of the plaque soft (echolucent)? Is >25% of the plaque soft (echolucent)?
Yes    No  Don’t know Yes       No  Don’t know 
Blood pressure =  /   
Systolic  Diastolic A C S T  O f f i c e  U s e  O n l y
ASYMPTOMATIC CAROTID SURGERY TRIAL
Carotid Duplex Follow-up Form
ACST/CDFU/1/401
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Analysis
Main  a nd  Subs id ia ry  Ana ly se s
The main comparisons will be of:
1 Stroke and death rates in the BMT plus surgery group versus medical treatment
alone in the first 4 months after randomisation and at yearly intervals to 5 years.
2. Duplex results in the medical treatment plus surgery group versus those having
medical treatment alone at the same intervals as in 1.
Subsidiary analyses in an effort to identify high and low risk groups will include:
The effect of risk factors such as the presence or absence of silent cerebral infarcts
on clinical outcome.
Other exploratory analyses will be performed to examine the data available
thoroughly.
Inter im Analyses  -  The Data Monitor ing Committee
During the study, interim analyses of major events will be supplied to the Data Monitoring
Committee.  They will advise the Steering Committee whether there is an unacceptably
high morbidity associated with surgery.  During follow-up further interim analyses will be
carried out.
The Data Monitoring Committee will advise the Steering Committee if there is:
1. proof beyond reasonable doubt* that for all or some types of patient one particular
treatment is contraindicated in terms of net difference in mortality or morbidity;
and
2. evidence that might reasonably be expected to influence materially patient
management by clinicians who are already aware of the results of other main trials.
* This cannot be specified precisely but a difference of at least 3 standard deviations in
an interim analysis of a major endpoint may be needed to justify halting or modifying
the study.
Should this happen and one treatment is clearly indicated or contra-indicated in terms of
net difference in mortality or stroke the trial would thereby influence patient management
and would either be stopped or modified to seek extra data.  The Trial Committee and
collaborators will otherwise remain ignorant of interim results.
The overall survival and major stroke free survival curves for both treatment groups will
be analysed.  These may cross because of greater hazards initially in the surgical group
during the perioperative period.  Similar life table analyses will be used to compare the
survival in unoperated groups with soft (echolucent) Gray Weale Type 1&2, and echodense
(Gray Weale Type 3&4) carotid plaques of differing stenoses.  As no minimum stenosis has
been specified, the range of stenoses entered and the proportion of plaque types cannot
be predicted until recruitment is well under way.
Validation of the Doppler technique will not be formally tested in each collaborating
centre.  It has been the practice of a number of centres to perform CEA without angiography
for some years.  Centres who screen with Doppler and perform angiograms may be
requested by the Data Monitoring Committee to provide angiography films on a randomly
selected sample of patients, to ensure that the relationship between Doppler stenosis and
angiography has a positive predictive value of around 90%. Simple Duplex data is requested
from the laboratories (see page 11).
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All patients undergoing CEA at each centre should be logged locally and a reason for not
putting them in the trial should be recorded, e.g. patient in ECST, or symptomatic with a
>70% stenosis.  A yearly request for local CEA logs will be sent to each centre.
Co n c lu s ion
A simple trial has been launched to answer the question ‘Does carotid endarterectomy
prevent disabling stroke or death in patients with asymptomatic carotid artery stenosis?’.
The normal practice of collaborating surgeons and physicians will be studied, and
appropriate best medical treatment will be given to all trial patients.  In addition to medical
treatment, one half of patients will undergo carotid endarterectomy.  Entering patients in
ACST-1 is simple and the trial is designed to minimise extra work for busy collaborators.
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APPENDIX:  Sample forms & Information Sheet
PATIENT INFORMATION SHEET: 1 (UK only)
TAKING PART IN RESEARCH
The Asymptomatic Carotid Surgery Trial
You are being invited to take part in a research project. Here is some information
to help you decide whether or not to take part. Please take time to read the
following information carefully and discuss it with friends, relatives and your
GP if you wish. Ask us if there is anything you do not understand or if you
would like more information. Take time to decide whether or not you wish to
take part. Thank you for reading this.
1. You may or may not receive any direct benefit from taking part in the study.
However, information obtained during the study may help us to understand
better your condition or illness. It may also help us in selecting treatment
for future patients.
2. It is up to you to decide whether to take part or not. If you do decide to take
part you will be given an information sheet and consent form. Even if you
do decide to take part, you are free to withdraw at any time and without
giving a reason. This will not affect the standard of care you will receive.
Your doctor will not be upset if you decide not to take part.
3. All the information collected about you during the study will be kept strictly
confidential. Any published report of the study will not identify you.
4. Your GP will usually be informed that you are taking part in this study. If this
is a problem for you, you should discuss it with your study researcher.
5. Sometimes during the study new information becomes available. Your study
doctor will talk to you about this and discuss with you whether you want to
continue in the study. If you decide to withdraw, the study doctor will make
arrangements for your care to continue. If you decide to continue in the
study you may be asked to sign an updated consent form.
6. Since this study may involve surgery, you will be asked to consent to that
surgery if and when it is allocated. You should understand that surgery is a
necessary part of this study and be happy to have the surgery if it is allocated,
before agreeing to take part.
7. If you have private medical insurance you should let the insurers know that
you intend to take part in a research project. They will be able to tell you if
this will affect your medical insurance.
8. Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical
Research and You’. This leaflet gives more information about medical research
and looks at some questions you may want to ask. You can obtain a copy
from:
CERES, PO Box 1365, London N16 0BW
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INVITATION TO JOIN A STUDY OF STROKE PREVENTION TREATMENT
The Asymptomatic Carotid Surgery Trial
We’d like to explain to you about the study we’re doing and then ask if you are
willing to help with it.
Background to the study: Every day in this country, lots of people have a stroke
or warning symptoms of a stroke. We are looking at some treatments that might
reduce the risk of stroke in patients who have a narrow carotid artery - that is the
artery that supplies blood to the part of the brain often affected by stroke. All
patients who may have an increased risk of stroke should receive medical treatment
and advice to help reduce this risk; this includes treatment of high blood pressure,
diabetes, high blood fat levels, heart disease and abnormally high red blood cell
counts whenever these are found. We will of course use all the standard treatments
for these problems.
An operation called carotid endarterectomy may, by successfully removing the
narrowing in the artery, reduce the risk of subsequent stroke. However, the risks
of this operation include an increased risk of stroke at the time of, and for a few
days after the operation. We know from other studies that the risk of operation is
justified in patients who have had warning symptoms of stroke (or a minor stroke)
provided that their carotid artery is narrowed by more than 70%. We are uncertain
whether medical treatment or an operation would be best for your condition.
Therefore we cannot definitely  recommend or discourage operation on present
evidence. The purpose of this study is to determine if carotid endarterectomy
reduces the risk of stroke in people who have had no previous warning symptoms.
Why have I been chosen? Your doctor has seen that you have a narrowing of
the carotid artery, but you haven’t yet had any symptoms related to that artery
(or you had symptoms but they occurred more than six months ago).
Who is organising the study? The study is international and is organised from
the Department of Cardiological Sciences at St. George’s Hospital Medical School,
London, UK. It is sponsored by the UK Medical Research Council (MRC).
What will happen to me if I take part? If you decide to take part you will
receive all the standard treatments which you would normally receive and you
will have the best medical care regardless of which arm of the study you are in. In
addition, you would agree to undergo carotid endarterectomy if selected to do
so. The selection is carried out at random by computer, and you have a 50% chance
of being selected for surgery. The operation would be carried out by your specialist
vascular surgeon, in exactly the same manner as he or she routinely does for other
patients. Everyone in the study will be followed up at 4 months, 12 months and
annually for at least five years by a visit to the surgeon and a repeat Doppler
carotid artery scan (which you have already had).
Are there other ways of treating my condition? There are standard medical
treatments for this condition, and all patients (whether assigned surgery or not)
will receive these in any case. There is also a procedure called carotid angioplasty
available.
APPENDIX:  Sample forms & Information Sheet
PATIENT INFORMATION SHEET: 2 (UK only)
Page 27
ACST-1 Protocol 2001 – page 17
APPENDIX:  Sample forms & Information Sheet
PATIENT INFORMATION SHEET: (UK only)
Are there any disadvantages in taking part in this study? You should
understand the reasons for taking any medicines and the possible symptoms which
might occur due to the narrow artery. If you have problems with these, you should
discuss this with your doctor.
What are the possible risks of taking part? The risks of surgery will be explained
by your doctor as well as the risks after operation.
What are the possible benefits of taking part? We hope that any treatment
you receive will reduce the risk of stroke. However, this cannot be guaranteed.
The information we get from this study may help us to treat future patients with
asymptomatic carotid disease better.
Is my doctor being paid for including me in the study? Neither your doctor
or the hospital will receive any payment for including you in this study.
What happens when the study stops? If the study stops and it is found that
the surgery is beneficial, then you will be offered the choice of having the surgery
(assuming you were not allocated surgery). If the study stops without being able
to tell if surgery is beneficial, it will be up to your doctor and yourself to decide if
you want surgery. If surgery is found not to be beneficial, then you will also be
informed by your doctor.
Are there any restrictions on what I might eat or do? If your cholesterol or
blood fats are high, or you have other medical conditions such as diabetes then
advice and appropriate treatment will be given. If you have heart disease or high
blood pressure your doctor will discuss and initiate suitable treatment with your
consent.
What if something goes wrong? If you are harmed by taking part in this study,
there are no special compensation arrangements. If you are harmed due to
someone’s negligence, then you may have grounds for a legal action. Regardless
of this, if you have any cause to complain about any aspect of the way you have
been approached or treated during the course of this study, the normal National
Health Service complaints mechanisms are available to you. The study is being
undertaken to seek treatments to prevent stroke. If you should have a stroke you
will be looked after by your doctors using the appropriate investigations,
treatments, and rehabilitation.
Confidentiality - who will know I am taking part in the study? The
information collected as part of the study will be sent to the central trial office,
who will hold it strictly confidential. Information on individual patients will not
be published as part of the trial results, and your name will never be released.
Your General Practitioner will usually be notified that you are participating in the
trial.
What will happen to the results of the study? The results of the study will be
communicated to the MRC, the Stroke Association, and peer-reviewed journals.
ACST/IL/1/401
Page 28
ACST-1 Protocol 2001 – page 18
Page 29
ACST-1 Protocol 2001 – page 19
APPENDIX:  Sample forms & Information Sheet
WRITTEN CONSENT FOR RANDOMISATION
ASYMPTOMATIC CAROTID
SURGERY TRIAL
Consent Form: (UK only)
Title of Project:
Name of Researcher:
Name and number of
independent person:
Please read each statement below and imitial eack box if you agree
1. I confirm that I have read and understand the
information sheets (version ACST/ILA/1/0998 and
ACST/ILB/1/098) for the above study.
2. I understand that my participation is voluntary and
that I am free to withdraw at any time without my
medical care or legal rights being affected.
3. I am willing to allow access to my medical records
but understand that strict confidentiallity will be
maintained. The purpose of this is to check that
the stury is being carried out correctly.
4. I agree to take part in the Asymptomatic Carotid
Surgery Trial.
_____________________________ _______________ _______________________
Name of Participant Date Signature
_____________________________ _______________ _______________________
Name of Person taking consent Date Signature
(if different from researcher)
_____________________________ _______________ _______________________
Researcher Date Signature
3 copies: 1 for participant; 1 for researcher; 1 to be kept with hospital notes
ACST/C/1/501
Asymptomatic Carotid  Surgery Trial (ACST)
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APPENDIX:  Sample forms & Information Sheet
RANDOMISATION FORM
1. Has the patient already signed their informed consent to enter this study? Yes  
2. Collaborator/Centre:  
3. Neurologist:
4. Patient's family name:
5. Patient's given name:
6. Patient's date of birth (day/month/year): / /
7. (UK or Holland only) GP's surname and postcode:
  
8. (Not UK & Holland) Relative (not husband/wife) name, phone no. (include area code):
 
  Name:
  Address:
(N.B. * means tick 1 answer ONLY)
* 9. Male     Female YES NO
* 10. Diabetic
* 11. Definite coronary artery disease
* I 2. Needs coronary bypass or angioplasty
* I 3. Currently taking: antihypertensive therapy
* 14. Currently taking: antiplatelet therapy
* 15. Currently taking: anticoagulant therapy
* 16. Currently taking: lipid lowering therapy
17. Total cholesterol (mmol/1): • OR mg/100ml: 
18. Present blood pressure (mmHg): Systolic Diastolic 
19. Duplex doppler % stenosis Left Right 
* 20. Is more than 25% of the plaque soft (echolucent)?
Left     Right     Both     None Don't know  
21. Infarct on CT scan Left     Right     Both     None Not done 
* 22. lnfarct on MRI scan Left     Right     Both     None Not done 
* 23. Which side are you considering surgery for? Left Right 
* 24. Any prior symptoms this side more than 6 months ago?
None        Amaurosis fugax Cortical TIA Stroke Other 
* 25. Any prior contralateral symptoms?
None        Amaurosis fugax Cortical TIA Stroke Other 
* 26. Previous CEA Left Right Both No 
ASYMPTOMATIC CAROTID SURGERY TRIAL
RANDOMISATION -Answer ALL questions
Then either:
phone: 0900-1700 UK time, weekdays,  or if unable to phone, you can fax:
England: (+44) (0)1865-240972 England (+44) (0)1865-404849 Reply within I working day.
Incomplete forms will be sent back for further details.
N.B. Patients in ECST must not be entered N.B. Return fax number must be given if faxed
ACST/R/3/501
Information to be obtained from phone call: Date: (day/month/year) / /
  Treatment allocated: Best medical treatment and surgery
OR Best medical treatment alone  
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APPENDIX:  Sample forms & Information Sheet
FOLLOW-UP FORM (OBVERSE)
Patient's family name:
Patient's given name:
Patient's date of birth (day/month/year): / /
If 1st follow-up after Trial Surgery, give date of operation: (day/month/year) / /
and side operated on Left Right 
Perioperative clinical myocardial infarct <30 days post CEA Yes No 
Any other carotid surgery since last follow-up Yes No 
If YES, give date of operation (day/month/year) / /
and side operated on Left Right 
Since randomisation/last follow-up
Left carotid territory symptoms Yes No 
Right carotid territory symptoms Yes No 
Any non-fatal stroke Yes          No   and date (day/month/year) / /
Patient died Yes          No   and date (day/month/year) / /
N.B. If answer to either is YES, complete major event form also (on reverse of this form)
Duplex results at this follow-up
Maximum % stenosis carotid artery Left    Right 
Any definite increase in plaque echolucency Left     Right     Both   None    Don’t know 
Current drug therapy
Antihypertensive Yes No 
Antiplatet Yes No 
Anticoagulant therapy Yes No 
Lipid lowering Yes No 
Current blood pressure Systolic    Diastolic 
Name of collaborator:
Neurologist:
Day (day/month/year): / /
Please return this form promptly to: ACST Trial Office
Department of Cardiological Sciences
St George’s Hospital Medical School
Cranmer Terrace
London SW17 0RE
or Fax (+44) (0)20 8725 3782
(see Reverse for Major Event Reporting)
ASYMPTOMATIC CAROTID SURGERY TRIAL
F O L L O W - U P
ACST/FU/3/501
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APPENDIX:  Sample forms & Information Sheet
FOLLOW-UP FORM (REVERSE)
Patient's family name:
Patient's given name:
Patient's date of birth (day/month/year): / /
Surgeon:
Neurologist:
History at randomisation: Give short account of history, particularly notable risk factors,
operative history and ECG, CT, angiogram and doppler plaque type results)
Follow-up (short account)
Event
a) Stroke: give date, side, neurological details and CT report of results with date (early to exclude
haemorrhage, later if normal at first to show infarct).
b) Death: give date, all details of cause and post mortem results (if done)
c) Any postoperative event (<30 days of surgery)
Details from operation notes, general description of operation, plaque appearence, degree of
stenosis found, exact time of death or stroke after operation (hours or days: please specify),
description of action taken and outcome, with CT results (early to exclude haemorrhage and
later if first CT normal) in patients who have stroke.
Please return this form promptly to: ACST Trial Office
Department of Cardiological Sciences
St George’s Hospital Medical School
Cranmer Terrace
London SW17 0RE
or Fax (+44) (0)20 8725 3782
ASYMPTOMATIC CAROTID SURGERY TRIAL
M A J O R  E V E N T
(complete if patient has a stroke or dies)
ACST/ME/3/501
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Second Asymptomatic Carotid Surgery Trial 
ACST-2 PROTOCOL SUMMARY (2007) 
ELIGIBILITY (potential, then definite)  
• 
 
 
 
• 
• 
Potential eligibility: Asymptomatic carotid stenosis that may well need procedural  
treatment with either carotid endarterectomy (CEA) or carotid artery stenting (CAS) 
The study can be mentioned and the ACST patient information leaflet given (or re-  
offered) either as soon as stenosis is found, or after further investigations, or both  
No symptoms from the stenosis (or none for some months), and no procedure  
previously performed on it. Any medical treatment (eg, statin, aspirin etc) already  
started; patient already recovered from any necessary coronary procedures (eg, CABG)  
Definite eligibility: MRA, CTA or other angiogram shows that CEA and CAS are  
both practicable: doctor substantially uncertain whether CEA or CAS is better  
(and sees no definite indication/contraindication for either*) 
INFORMATION LEAFLET (can be re-offered) & consent  
• 
• 
• 
Potentially and definitely eligible patients: mention the study and give (or re-offer)  
information leaflet (with an ACST doctor's name written onto the consent form) for the  
patient to read and discuss now and/or take away to consider and discuss later  
If the patient is then also substantially uncertain between CEA and CAS and is  
willing and eligible to join ACST, invite witnessed signature of the consent form  
Consent requires address of patient (for annual follow-up letter), of family doctor and of 1  
or 2 friends or relatives (in case contact is lost). The information leaflet asks the patient to 
bring these along, but clinic staff may need to help the patient get them fully completed  
ENTRY (by telephone randomisation)  
• 
•
• 
Complete at least part 1 of the randomisation form before telephoning to enter the  
patient, as these details are needed in the phone call. (The rest can be done later.)  
Ring the randomisation service +44 (0)18 65 76 56 15 to obtain the treatment  
allocation (CEA/CAS) and a 6-digit patient ID number  
Tell the patient which procedure (CEA/CAS) they have been allocated, and plan for  
that procedure to be done as soon as possible  
PROCEDURE (performance, and 1-month follow-up)  
• 
• 
 
 
 
• 
A collaborator with an approved Track Record for performing the allocated procedure  
does it, using their normal CEA/CAS techniques (& approved materials)  
Before discharge, schedule a follow-up about 1 month later for:  
- duplex ultrasound (to check carotid patency)  
- examination by neurologist/stroke physician  
(to assess & describe any peri-or post-operative stroke or MI)  
Complete and return the 1-month post-procedural form (stroke, MI or death);  
routine annual follow-up is then by letters to the patient from the ACST office  
Randomisation: telephone +44 (0) 18 65 76 56 15  
Website: www.acst.org.uk  
 
* Reasons for not randomising are specified not by the protocol but by the responsible doctor, and might include 
– either only a small likelihood of worthwhile benefit – or a high risk of adverse events from CEA or from CAS 
• Very low risk of stroke (eg, very minor stenosis)  • Access anatomically difficult either for CEA or for CAS  
• Some major life-threatening disease (eg, advanced cancer)  • Unfit for surgery (eg, severe heart failure)
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